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C Segré 
European School of Molecular Medicine, IFOM-IEO Campus, via Adamello 16, 20081, Milan, Italy 
Abstract 
The  4th International PhD Student Cancer Conference was held at the IFOM-IEO-Campus in Milan from 19–21 May 2010 
http://www.semm.it/events_researchPast.php
The Conference covered many topics related to cancer, from basic biology to clinical aspects of the disease. All attendees presented 
their research, by either giving a talk or presenting a poster. This conference is an opportunity to introduce PhD students to top cancer 
research institutes across Europe.  
The core participanting institutes included: 
•  European School of Molecular Medicine (SEMM)—IFOM-IEO Campus, Milan 
•  Beatson Institute for Cancer Research (BICR), Glasgow 
•  Cambridge Research Institute (CRI), Cambridge, UK 
•  MRC Gray Institute of Radiation Biology (GIROB), Oxford 
•  London Research Institute (LRI), London 
•  Paterson Institute for Cancer Research (PICR), Manchester 
•  The Netherlands Cancer Institute (NKI), Amsterdam 
‘You organizers have crushed all my prejudices towards Italians. Congratulations, I enjoyed the conference immensely!’ Even if it might 
have sounded like rudeness for sure this was supposed to be a genuine compliment (at least, that’s how we took it), also considering that 
it was told by a guy who himself was the fusion of two usually antithetical concepts: fashion style and English nationality. 
The year 2010 has marked an important event for Italian research in the international scientific panorama: the European School of 
Molecular Medicine (SEMM) had the honour to host the 4th International PhD Student Cancer Conference, which was held from 19–21 
May 2010 at the IFOM-IEO-Campus (http://www.semm.it/events_researchPast.php) in Milan. 
The conference was attended by more than one hundred students, coming from a selection of cutting edge European institutes devoted 
to cancer research. The rationale behind it is the promotion of cooperation among young scientists across Europe to debate about 
science and to exchange ideas and experiences. But that is not all, it is also designed for PhD students to get in touch with other 
prestigious research centres and to create connections for future post docs or job experiences. And last but not least, it is a golden 
chance for penniless PhD students to spend a couple of extra days visiting a foreign country (this motivation will of course never be 
voiced to supervisors). 
The network of participating institutes has a three-nation core, made up of the Netherlands Cancer Institute, the Italian European School 
of Molecular Medicine (SEMM) and five UK Cancer Research Institutes (The London Research Institute, The Cambridge Research 
Institute, The Beatson Institute for Cancer Research in Glasgow, The Patterson Institute for Cancer Research in Manchester and the 
MRC Gray Institute for Radiation Oncology and Biology in Oxford).  
The conference is hosted and organised every year by one of the core institutes; the first was in Cambridge in 2007, Amsterdam in 2008 
and London in 2009, this year was the turn of Milan. 
In addition to the core institutes, PhD students from several other high-profile institutes are invited to attend the conference. This year 
participants applied from the Spanish National Cancer Centre (CNIO, Madrid), the German Cancer Research Centre (DKFZ, Heidelberg), 
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the European Molecular Biology Labs (EMBL, Heidelberg) and the San Raffaele Institute (HSR, Milan). Moreover four ‘special guests’ 
from the National Centre for Biological Sciences of Bangalore (India) attended the conference in Milan.  This represents a first step in 
widening the horizons beyond Europe into a global worldwide network of talented PhD students in life sciences. 
The conference spread over two and a half days (Wednesday 19th to Friday 21st  May) and touched on a broad spectrum of topics: from 
basic biology to development, from cancer therapies to modelling and top-down new generation global approaches. The final selection of 
presentations has been a tough task for us organisers (Chiara Segré, Federica Castellucci, Francesca Milanesi, Gianluca Varetti and 
Gian Maria Sarra Ferraris), due to the high scientific level of the abstracts submitted. In the end, 26 top students were chosen to give a 
15-min oral presentation in one of eight sessions: Development & Differentiation, Cell Migration, Immunology & Cancer, Modelling & 
Large Scale approaches, Genome Instability, Signal Transduction, Cancer Genetics & Drug Resistance, Stem Cells in Biology and 
Cancer. 
The scientific programme was further enriched by two scientific special sessions, held by Professor Pier Paolo di Fiore and Dr Giuseppe 
Testa, Principal Investigators at the IFOM-IEO-Campus and by a bioethical round table on human embryonic stem cell research 
moderated by Silvia Camporesi, a senior PhD student in the SEMM PhD Programme ‘Foundation of Life Science and their Bioethical 
Consequences’. 
On top of everything, we had the pleasure of inviting, as keynote speakers, two leading European scientists in the fields of cancer 
invasion and biology of stem cells, respectively: Dr Peter Friedl from The Nijmegen Centre for Molecular Life (The Netherlands) and 
Professor Andreas Trumpp from The Heidelberg Institute for Stem Cell Technology and Experimental Medicine (Heidelberg).  
All the student talks have distinguished themselves for the impressive quality of the science; an encouraging evidence of the high profile 
level of research carried out in Europe. It would be beyond the purposes of this report to summarise all 26 talks, which touched many 
different and specific topics. For further information, the Conference Abstract book with all the scientific content is available on the 
conference Web site (http://www.semm.it/events_researchPast.php). In what follows, the special sessions and the keynote lectures will 
be discussed in detail. 
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19 May 2010 
Special Scientific Session I: Giuseppe Testa, 
PhD (IEO, Milano) 
Priming the epigenome in development and cancer 
The conference had a flying start with a talk by Giuseppe Testa, 
Principal Investigator of the Histone Methylation in Stem Cell 
Renewal and Lineage Commitment Laboratory at the European 
Institute of Oncology, Milan. 
It has been well established that the lineage commitment of a 
cell as well as the persistence of a specific differentiation stage 
is regulated by the modulation of its chromatin state through a 
code of epigenetic modifications of histone tails. Among the 
many modifications involved, methylation of histone H3 on 
lysine 4 (associated with active transcription) and on lysine 27 
(associated with active transcription) reside at the centre of this 
network. Defined patterns of histone methylation are 
characteristic of different physiologic stages of differentiation, 
from pluripotency to terminal differentiation. Aberrant, stem cell 
like perturbations of the epigenetic patterns are common in 
cancer, where the cells reacquire a less differentiated, more 
proliferative phenotype. For example, repressive 
hypermethylation is found on the promoters of many tumour 
suppressor genes.  
The work of Giuseppe’s laboratory is aimed at the decodification 
of the epigenetic code during both normal differentiation and 
oncogenesis.  They have identified the existence of bivalent 
domains for both H3K4me3 and H3K27me3 on the promoter of 
different genes in undifferentiated, precursor cells. The 
resolution of the bivalent domain towards complete 
transcriptional activation (only H3K4me3) or transcriptional 
repression (only H3K27me3) leads cells to commitment and 
differentiation. 
Giuseppe Testa’s laboratory is also at the forefront on another 
‘hot field’ in modern biology; the elucidation of epigenetic 
changes driving the re-programming of somatic cells into 
induced pluripotent stem cells (IPs). 
The ectopic expression of defined transcriptional factors was 
shown to induce the reacquisition of stem cell like properties [1], 
but the molecular details of this re-programming are largely 
unknown. A critical role is likely to be played by the histone
methyl transferase Ezh2, a member of the polycomb group 
protein responsible for the trimethylation of lysine 27 on histone 
H3. This mechanistic relationship is being extensively 
investigated by Giuseppe Testa and his team. 
Although the pattern of epigenetic markers and the chromatin 
state of IPs is more similar to that of an embryonic cell rather 
than a fully committed cell, IPs do not show the exact, 
equivalent pattern of epigenetic modifications as embryo-
derived pluripotent cells. These striking observations not only 
complicate the picture of the mechanisms on the basis of 
cellular commitment and re-programming, but also raise 
relevant issues for therapeutic applications in medicine and in 
the public debate about this sensitive field of biological 
investigation.  
One of the big promises and expectations of IPs is in fact the 
application in regenerative medicine and gene therapy. If it is 
possible to re-programme a somatic, committed cell to 
reacquire stem-like properties, it will be virtually possible to take 
adult cells from a patient, engineer them to treat the relevant 
pathology and re-programme them to be re-injected into the 
patient. This is perceived by public opinion as the magic wand 
that will solve once and for all the ethical dilemma of using 
human embryonic stem cells. But, in light of these new results, 
is this still so straightforward? Could IPs really substitute hES in 
every circumstance? It is not possible to have a clear answer 
yet, so further research in the IP and hES fields is required over 
the next decade. The ethical and social implications of IPs were 
also partially discussed during the Bioethics Round table on 
May 20th. 
 
Keynote Lecture I: Dr. Peter Friedl (The 
Nijmegen Centre for Molecular Life, The 
Netherlands) 
Plasticity of cancer invasion and implications for 
therapy 
It is not an easy job to keep the audience’s eyes fixed on the 
screen for more than one hour especially if you happen to be 
the last speaker of a densely scheduled day and much of your 
audience woke up at 4 pm (I hope you mean 4 am) to catch a 
flight, but Dr Peter Friedl succeeded in doing this. 
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He presented the results of his studies on cancer migration in 
living orthotopic fibrosarcoma xenograft mice, using the 
infrared-excited multiphoton microscopy (IR-MPM). With this 
avant-garde technology, it is possible to obtain three-
dimensional images of tissues, resolving structures such as 
collagen fibres of the extracellular matrix, neural networks and 
blood vessels in living animals. It is really like opening a window 
on an organism and studying in real time the evolution of a 
biological phenomenon. Dr Friedl and his team injected tumour 
cells into recipient mice and applied IR-MPM to study how 
malignant cells start to migrate from the primary mass to 
metastatise. 
The classical paradigm of metastatic onset and invasion is the 
so-called epithelial to mesenchymal transition, which defines the 
process through which cells acquire the ability to actively 
migrate through the extracellular environment. Cells can migrate 
in a dispersed, amoeboid way, or (as Friedl suggests) in a 
collective way. In his model cells at the front works as 
pacesetters in secreting collagenase, and a strand of many 
other cells follow as synchronously as a super-cell. 
Interestingly, Dr Friedl clearly showed how in the living tissues 
tumour cells branched from the central mass and migrate as 
multicellular structures following pre-existing ‘highways’, such 
as tissue blood vessels (but, interestingly, not along neo-
tumour-induced blood vessels). Cells can move with a speed of 
up to 200 µm per day and are also actively proliferating. 
The IR-MPM was then used to study the response to radiation 
therapy. Strikingly, the perivascular, migrating cells were 
resistant to the treatment, while the vast majority of resting cells 
of the primary mass underwent apoptosis. Only the concomitant 
ablation of ß1 and ß3 integrins, which are very well 
characterised molecular actors in cellular migrations, was able 
to sensitise invasive cells to radiation, suggesting a central role 
of integrin-dependent signalling in response to radiotherapy.   
A preliminary, combinatorial treatment with antibodies against 
integrin ß1 and subsequent irradiation was shown to be the only 
way to effectively eradicate all the migrating branches of the 
tumour mass in vivo. 
Moreover, the notion that malignant cells prefer physiological 
microenvironments such as normal perivascular areas rather 
than new cancer-induced vessels is an essential concept for 
understanding the mechanisms of invasion and metastatisation 
and will be important for future cancer therapies. 
20 May 2010 
Special Scientific Session II: Professor Pier 
Paolo Di Fiore (IFOM, Milano)  
Endocytosis and re-cycling at the crossroads of 
signalling, attenuation, execution of polarized 
functions and cell fate determination 
The  4th International PhD Student Cancer Conference would 
have not been possible without the support of the European 
School of Molecular Medicine (SEMM), but the SEMM itself 
would not be a reality without the efforts of one of its principal 
co-founders, Professor Pier Paolo Di Fiore, whom we had the 
great pleasure to have as a special speaker. Pier Paolo Di Fiore 
is Principal Investigator in the Endocytosis, Signalling and 
Cancer Laboratory at IFOM, Milan. 
Endocytosis of membrane receptor tyrosine kinases has 
traditionally been considered simply as a way for cells to 
attenuate long-term extracellular signalling. In recent years, 
many studies have shown that endocytosis is far more than 
that. Receptors are internalised into endosomes, which have 
been shown not to be simple ‘storage’ vesicles but complex 
structures where important decisions are taken. Receptors are 
degraded or recycled on the membrane according to the 
intensity of the extracellular stimuli; endosomes work as a 
platform for the integration of extracellular information into a 
complex network to execute important functions such as the 
establishment of cell polarity and cell motility. Among the many 
proteins and effectors involved, Numb is of particular interest 
since it is implied in the negative regulation of notch receptor 
signalling in actin and cytoskeletal dynamics. 
Moreover, Numb is not only involved in endocytosis, but is also 
an important cell fate determinant in stem and progenitor cells. 
Stem cells are undifferentiated cells able to give rise to a variety 
of differentiated cell types when induced by differentiation 
stimuli. They normally represent a minor part of cell populations 
in tissues and they are in a quiescent state respect to the more 
committed, proliferative cells. 
Taking advantage from this concept, Prof. di Fiore together with 
Prof. Pier Giuseppe Pelicci have established an elegant 
experimental technique aimed at isolating and cultivating 
mammary stem cells (MSC). 
Cells are stained with a red dye, PKH, which is retained in the 
cell membrane and is diluted in the daughter cells at every cell
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division. The more a cell is proliferating, the faster the dye will 
be diluted and the cells will loose the red colour. Cells that 
instead are quiescent, i.e. stem cells or precursors, will retain 
the dye and will appear red coloured, so that they and can be 
easily identified and purified. 
Another key feature of stem cells is the ability to undergo not 
only symmetric division (which gives origin to two identical 
daughter cells more committed than the mother cell to linage 
determination), but also asymmetric division; one of the two 
cells retains the properties of the mother stem cells, thus 
maintaining the stem cell pool, while the other cell is committed 
to differentiation. 
Using the PKH technique to enrich the stem cell content of 
cellular populations, Prof. di Fiore and his team discovered that 
Numb is differentially parted during asymmetric division in MSC: 
it is retained in the quiescent, stem cell while the other daughter 
cell acquires a differentiation fate and starts replicating 
symmetrically, loosing stem cell potential. Numb acts as a cell 
fate determinant because of its ability to silence the notch 
signalling pathway associated with differentiation and to positive 
regulate p53 in the MSC. 
Fifty per cent of breast cancers show a decreased expression of 
numb, which is associated with a poor prognosis [2].  The 
findings that numb affects the regulation of the mammary stem 
cell compartment will likely have a great clinical relevance and 
will help to design more specific and effective pharmacological 
treatments. 
 
Special Session III-Bioethics round table: 
Worldwide human embryonic stem cells 
policies: Who decides and on what 
grounds? 
Moderated by Silvia Camporesi (PhD 
student, in the SEMM PhD programme in 
Foundation of Life Science and Their 
Bioethical Consequences – FOLSATEC) 
The FOLSATEC is a unique, multidisciplinary PhD programme 
open to students with a scientific or philosophical background. It 
aims to create specialised scholars in the fields of ethical 
analysis and relationships between biomedicine and society. 
We could not miss the chance to include an interactive round 
table on bioethics in the conference programme. 
Silvia Camporesi, a Senior FOLSATEC PhD student, gave a 
general but exhaustive summary of the current bioethical 
debate regarding research on human embryonic stem cells 
(hES cells). All the classical arguments against the use of hES 
cells were analysed, followed by counterarguments. The second 
part of the session was focused on an overview of the different 
hES cell policies in various countries. 
The first argument used by opposers of hES cells is the so-
called wisdom of repulsion enunciated by the American 
bioethicist Leon Kass, Chair of the US President's Council on 
Bioethics from year 2002–2005, during the George W Bush 
administration.  
According to him, the innate sense of repulsion towards 
something is the ‘expression of a deep wisdom, beyond 
reason’s power to fully articulate it’. Silvia replied with the words 
of one of the leading contemporary bioethicists, John Harris, 
Director of the Research Centre for the Institute for Science, 
Ethics and Innovation in Manchester (UK). It is not reasonable 
to use an ‘emotional, olfactory argument’ into a rigorous and 
logic debate. Moreover, it should be remembered that the 
‘wisdom of repulsion’ has been used in the past to morally 
justify a presumed superiority of race and sex, which then 
science demonstrated to be totally groundless. 
Another strong argument always proposed against the use of 
hES is the possibility to completely substitute them with IPs. But 
as Giuseppe Testa pointed out in his talk, IPs and ES cells are 
not identical. Moreover, the know-how that brought to the 
technology of IPs was mainly gained through research on 
embryonic stem cells. The most sensible approach will then be 
to pursue parallel research in both IPs and hES fields and 
exchange knowledge and technologies. 
In the second part of the session, the current policies regarding 
hES of United States, United Kingdom, Germany and Italy were 
compared; the emerging picture was very heterogeneous and 
confusing, with peaks of depressing hypocrisy such as in the 
case of Italy, where the research is banned on hES created 
within the national boundaries but it can be done on hES cells 
lines imported from abroad. 
The third part was dedicated to debate the illustrated topics with 
the audience; two main interesting considerations emerged. 
First, the different moral status societies give to embryonic stem 
cells on the basis of the ‘specie of origin’. There are in general 
no moral complaints about the use of animal embryonic stem 
cells, such as murine ones. This could be due, in part, to an 
innate ‘sense of empathy’ that we have towards something we
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perceive as being human, or having the potential to become 
human. In other words, our vision of the world is anthropo-
centric and not mouse-centric; but is this argument strong 
enough from a logic and rational perspective to be used against 
human stem cell research? Is this argument strong enough to 
bypass all the possible good applications (such as regenerative 
medicine) that could arise from knowledge acquired in the hES 
cell research field? 
Of course, we could not give a definitive answer; the debate is 
still open and it will likely be a ‘hot topic’ not only for the 
scientific and ethical communities but for democratic societies 
worldwide for many years to come. 
The second issue of debate sprouted from the comparison of 
stem cell policies around the world. Everyone was convinced 
that the most urgent issue, beyond all the different approaches 
to the problem, is the realisation of a clear, unambiguous and 
globally uniform legislation in terms of use and derivation of 
human embryonic stem cells. 
 
21 May 2010 
Keynote Lecture II: Professor Andreas 
Trumpp (DKFZ and Heidelberg Institute for 
Stem Cell Technology and Experimental 
Medicine, Heidelberg) 
Dormancy in normal and malignant stem cells 
Since the enunciation of the ‘golden rule’ of cancer onset and 
progression by Hanahan and Weinberg at the beginning of the 
XXI century [3], another revolutionary concept has changed the 
way scientists and physicians look (or should look) at cancer in 
the last years. To paraphrase a famous quotation: ‘All the 
malignant cells are tumoural, but some are more tumoural than 
others’ [4]. That is, the tumour can be seen as an anarchist 
tissue inside the normal ones, with a hierarchy of 
heterogeneous cells; a population of differentiated, though 
malignant, cells and a few, pluripotent cells sustaining the 
growth and expansion of the whole mass. 
Cancer stem cells have been now identified in many types of 
cancers; Professors Pier Paolo di Fiore and Pier Giuseppe 
Pelicci recently isolated breast cancer stem cells and 
demonstrated that they are not only responsible for the onset 
and growth of breast cancers, but also for the aggressiveness of 
the tumour. Cancer tissues with a higher number of malignant 
stem cells are more aggressive than cancers with a low number 
[5]. 
But the picture is even more complex, as Professor Trumpp 
masterly showed during his lecture. In fact, not all the stem cells 
are active; a sub-population can enter a resting state, defined 
as ‘dormancy’. These cells can create a suitable 
microenvironment, a niche, both in the tissue of the primary 
tumour or in a metastatic tissue. This ‘lethargy-like’ condition 
can be maintained by stem cells for a long time, even years, 
waiting to be ‘awaken’ by stress or injury stimuli such as 
interferon alpha or LPS [6].  It is not hard to imagine the impact 
that this new discovery will have on the way cancer is 
approached as a disease. New-generation drugs and therapies 
should be not only targeted to cancer stem cells more than the 
main tumour mass, but they should ideally be able to interfere 
with the dormant, not active stem cells directly on them or 
affecting somehow the establishment and/or maintenance of 
their proper niche. From a clinical point of view, this could lead 
to the eventuality to extend the temporal threshold of ‘remission’ 
far longer the canonical 5 years, with practical implications for 
example on cancer patient follow-up during time. But the 
science of stem cell biology is dawning now and many studies 
and discoveries will likely come in the next decades. 
Besides all the excellent science, there has also been time for 
relaxing and social events. On the evening of the 19th we 
enjoyed pizza and the warm, jasmine-smelling air of mid-May at 
the IFOM-IEO-Campus bar. 
The 360° view of the Milan by night was the frame of the Social 
Dinner at the Skyline Restaurant on the evening of the 20th 
May. 
But since science and research never stop, it is already time to 
look forward: the 5th edition of the International PhD Student 
Cancer Conference will take place at The Beatson Institute for 
Cancer Research in Glasgow from 15–17 June 2011 (http:// 
www.beatson.gla.ac.uk/Student-Conference-2011.html). Emi- 
nent scientists such as Gerard Evan and Nobel Prize winner Sir 
Tim Hunt will be giving lectures, and everyone is looking 
forward to attending what has clearly become an established 
and fruitful tradition in the panorama of European science. 
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